NCT01207323View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 9, 2010

Primary Completion Date

December 3, 2013

Study Completion Date

April 23, 2018

Conditions
Epithelial Tumors, Malignant
Interventions
DRUG

MEHD7945A

MEHD7945A will be administered as specified in the individual arms.

Trial Locations (6)

28050

HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid

46010

Hospital Clinico Universitario de Valencia, Valencia

77030

University of Texas M.D. Anderson Cancer Center, Houston

80045

Uni of Colorado Cancer Center; Anschutz Cancer Pavilion, Aurora

02114

Massachusetts General Hospital., Boston

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY